Farmacovigilância no tratamento com peginterferon e ribavirina em pacientes com hepatite C crônica no serviço de hepatologia do Hospital Universitário de Aracaju-SE

• Ano de defesa: 2011
• Autor(a) principal: Nogueira, José Barreto Cruz
• Orientador(a): Quintans Júnior, Lucindo José
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Sergipe
• Programa de Pós-Graduação: Pós-Graduação em Ciências da Saúde
• País: BR
• Palavras-chave em Português: Farmacovigilância; Hepatite C crônica; Reações adversas; Peginterferon; Ribavirina
• Palavras-chave em Inglês: Pharmacovigilance; Chronic hepatitis C; Adverse reactions; Peginterferon; Ribavirin
• Área do conhecimento CNPq: CNPQ::CIENCIAS DA SAUDE
• Link de acesso: https://ri.ufs.br/handle/riufs/3715

Hepatitis C is an infectious disease with an overall prevalence of 2.2% and Brazil 1.5%. Drug therapy consists of interferon α, peginterferon α and ribavirin. It is filled with aggressive treatment of adverse reactions, hence the importance of pharmacovigilance as an additional tool in monitoring the treatment and rational use of medicines. Thus, adverse reactions occurred in patients with chronic hepatitis C who were treated with peginterferon and ribavirin, were identified and quantified through a retrospective and observational study. The most prevalent reactions observed in 46 patients in the study, were: fatigue (84.8%), fever (82.6%), loss weight (80.4%), irritability (73.9%) and body pain (71.7%). Most reactions were classified as mild (95.1%), while like moderate, 4.5% and as serious, 0.4%. The adverse reactions caused the therapeutic management in 11 patients (23.9%) where it was, dose reduction for 7 patients (15.2%), temporary discontinuation of the treatment for 5 patients (10.9%) and permanent discontinuation for 3 patients (6.5%). Eleven potential drug interactions were identified in 9 patients (19.6 %), where the most frequent was among peginterferon α 2a and captopril (45.4%). Said that, it s noticed that the treatment for chronic hepatitis C is marked for many adverse reactions with variable severity, that may interfere on patient s quality of life or in compliance of the treatment and this may be exacerbated by potential drug interactions. Additionally we evaluated the pharmacovigilance system of the Hepatology service of the University Hospital of the Federal University of Sergipe of patients registered from January 2007 to July 2009.